$ALXO
ALX ONCOLOGY HOLDINGS INC Stock $alxo

$alxo Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000095017023021247 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.295M	$7.440M	$7.674M
YoY Change	3.61%	-3.05%	76.01%
% of Gross Profit
Research & Development	$29.48M	$24.76M	$17.07M
YoY Change	10.22%	45.04%	73.35%
% of Gross Profit
Depreciation & Amortization	$207.0K	$213.0K	$58.00K
YoY Change	146.43%	267.24%	1060.0%
% of Gross Profit
Operating Expenses	$36.78M	$32.20M	$24.75M
YoY Change	8.84%	30.13%	74.18%
Operating Profit	-$36.78M	-$32.20M	-$24.75M
YoY Change	8.84%	30.13%	74.18%
Interest Expense	$372.0K	$387.0K	$225.0K
YoY Change	-57.53%	72.0%	800.0%
% of Operating Profit
Other Income/Expense, Net	$324.0K	$95.00K	-$11.00K
YoY Change	-4728.57%	-963.64%	450.0%
Pretax Income	-$34.16M	-$30.18M	-$24.53M
YoY Change	3.76%	23.03%	72.95%
Income Tax
% Of Pretax Income
Net Earnings	-$34.16M	-$30.18M	-$24.53M
YoY Change	3.76%	23.03%	72.95%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.84	-$0.74	-$0.60
Diluted Earnings Per Share	-$0.84	-$0.74	-$604.0K
COMMON SHARES
Basic Shares Outstanding	40.87M	40.86M	40.63M
Diluted Shares Outstanding	40.88M	40.86M	40.62M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$212.8M	$227.9M	$316.6M
YoY Change	-32.08%	-28.0%	-26.36%
Cash & Equivalents	$38.04M	$63.19M	$159.1M
Short-Term Investments	$174.8M	$164.8M	$157.5M
Other Short-Term Assets	$6.725M	$4.592M	$4.929M
YoY Change	93.19%	-6.84%	97.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$219.6M	$232.5M	$321.5M
YoY Change	-30.7%	-27.68%	-25.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.828M	$3.932M	$1.338M
YoY Change	134.85%	193.87%	2746.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$11.65M	$28.22M	$25.11M
YoY Change	7.25%	12.39%
Other Assets	$10.90M	$13.45M	$15.70M
YoY Change	-34.68%	-14.35%	2829.85%
Total Long-Term Assets	$26.37M	$45.60M	$42.15M
YoY Change	-9.6%	8.19%	7130.02%
TOTAL ASSETS
Total Short-Term Assets	$219.6M	$232.5M	$321.5M
Total Long-Term Assets	$26.37M	$45.60M	$42.15M
Total Assets	$245.9M	$278.1M	$363.7M
YoY Change	-28.93%	-23.52%	-15.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.115M	$9.826M	$5.133M
YoY Change	-52.59%	91.43%	-30.16%
Accrued Expenses	$13.46M	$11.63M	$9.746M
YoY Change	-9.34%	19.31%	260.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$429.0K
YoY Change	-100.0%	-100.0%	329.0%
Total Short-Term Liabilities	$17.57M	$21.89M	$15.31M
YoY Change	-26.64%	43.0%	8.34%
LONG-TERM LIABILITIES
Long-Term Debt	$9.512M	$9.450M	$175.0K
YoY Change	13488.57%	5300.0%	75.0%
Other Long-Term Liabilities	$6.156M	$6.409M	$4.772M
YoY Change	7.12%	34.3%	1506.73%
Total Long-Term Liabilities	$15.67M	$15.86M	$4.772M
YoY Change	172.63%	232.33%	1506.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.57M	$21.89M	$15.31M
Total Long-Term Liabilities	$15.67M	$15.86M	$4.772M
Total Liabilities	$33.24M	$37.75M	$20.08M
YoY Change	11.92%	88.0%	39.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$389.8M	-$355.7M	-$226.5M
YoY Change	50.25%	57.01%	70.69%
Common Stock	$602.8M	$596.1M	$570.7M
YoY Change	4.47%	4.45%	3.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$212.7M	$240.4M	$343.6M
YoY Change
Total Liabilities & Shareholders Equity	$245.9M	$278.1M	$363.7M
YoY Change	-28.93%	-23.52%	-15.99%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$34.16M	-$30.18M	-$24.53M
YoY Change	3.76%	23.03%	72.95%
Depreciation, Depletion And Amortization	$207.0K	$213.0K	$58.00K
YoY Change	146.43%	267.24%	1060.0%
Cash From Operating Activities	-$31.71M	-$27.82M	-$20.67M
YoY Change	86.56%	34.55%	302.61%
INVESTING ACTIVITIES
Capital Expenditures	$1.739M	$690.0K	$589.0K
YoY Change	-776.65%	17.15%	8314.29%
Acquisitions
YoY Change
Other Investing Activities	$7.952M	$42.99M	-$183.3M
YoY Change	-110.48%	-123.45%
Cash From Investing Activities	$6.213M	$42.30M	-$183.9M
YoY Change	-108.16%	-123.0%	2627342.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	343.0K	-107.0K	80.00K
YoY Change	-18.72%	-233.75%	-89.72%
NET CHANGE
Cash From Operating Activities	-31.71M	-27.82M	-20.67M
Cash From Investing Activities	6.213M	42.30M	-183.9M
Cash From Financing Activities	343.0K	-107.0K	80.00K
Net Change In Cash	-25.16M	14.37M	-204.5M
YoY Change	-72.87%	-107.03%	4586.41%
FREE CASH FLOW
Cash From Operating Activities	-$31.71M	-$27.82M	-$20.67M
Capital Expenditures	$1.739M	$690.0K	$589.0K
Free Cash Flow	-$33.45M	-$28.51M	-$21.26M
YoY Change	99.81%	34.06%	313.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001810182
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39386
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ALX ONCOLOGY HOLDINGS INC
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-0642577
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	323 Allerton Avenue
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40861386
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023Q1	dei	City Area Code CityAreaCode	650
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	466-7125
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	ALXO
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40869135
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63194000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48822000
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	164750000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	217385000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4592000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4762000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	232536000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	270969000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3932000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3889000
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	28220000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	16699000
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13450000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14932000
CY2023Q1	us-gaap	Assets Assets	278138000
CY2022Q4	us-gaap	Assets Assets	306489000
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9826000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8073000
CY2023Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	830000
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1650000
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11235000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18602000
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	21891000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28325000
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9450000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9389000
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6409000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5311000
CY2023Q1	us-gaap	Liabilities Liabilities	37750000
CY2022Q4	us-gaap	Liabilities Liabilities	43025000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40863049
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40863049
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40861386
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	240388000
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	41000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	41000
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	596086000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	589735000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-88000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-845000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-355651000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-325467000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	240388000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	263464000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	278138000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	306489000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24763000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17073000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7440000
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7674000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	32203000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	24747000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-32203000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24747000
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2311000
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	225000
CY2023Q1	us-gaap	Interest Expense InterestExpense	387000
CY2022Q1	us-gaap	Interest Expense InterestExpense	3000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	95000
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30184000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24533000
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40862513
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40862513
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40616302
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40616302
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30184000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24533000
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	757000
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-606000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29427000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25139000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	263464000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6351000
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	757000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30184000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	363049000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63260000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	159152000
CY2023Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	1711000
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	185000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5501000
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-606000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24533000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	343596000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-30184000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-24533000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	213000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	58000
CY2023Q1	alxo	Operating Finance Lease Right Of Use Asset Amortization Expense OperatingFinanceLeaseRightOfUseAssetAmortizationExpense	305000
CY2022Q1	alxo	Operating Finance Lease Right Of Use Asset Amortization Expense OperatingFinanceLeaseRightOfUseAssetAmortizationExpense	318000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6351000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5501000
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1114000
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-107000
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	61000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-170000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1577000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1177000
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	317000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1767000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1553000
CY2023Q1	alxo	Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent	-820000
CY2022Q1	alxo	Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent	-184000
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-5551000
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1304000
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-191000
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-296000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27816000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20674000
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	72204000
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	183332000
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	115189000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	690000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	589000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	42295000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-183921000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	185000
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	107000
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	105000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-107000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	14372000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-204515000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48888000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	363667000
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	147000
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3419000
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63194000
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	616000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	159086000
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	66000
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	66000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63260000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	159152000
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Certain amounts in the prior period have been reclassified to conform to the current period presentation.</span></p>
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including, but not limited to, those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, fair value of investments and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	403000
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	252270000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	274258000
CY2022Q3	us-gaap	Cash Cash	3900000
CY2022Q4	us-gaap	Cash Cash	8600000
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	224050000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	257559000
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	28220000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	16699000
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	252270000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	274258000
CY2023Q1	alxo	Fair Value Assets And Liabilities Transfers Amount FairValueAssetsAndLiabilitiesTransfersAmount	0
CY2022Q1	alxo	Fair Value Assets And Liabilities Transfers Amount FairValueAssetsAndLiabilitiesTransfersAmount	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	800000
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	1000000.0
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	28400000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2023Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4548000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4292000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	1305000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3932000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3889000
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5433000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5626000
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	186000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	298000
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	144000
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	144000
CY2023Q1	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	182000
CY2022Q4	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	78000
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	66000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	66000
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13450000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14932000
CY2023Q1	alxo	Accrued Clinical And Non Clinical Costs Current AccruedClinicalAndNonClinicalCostsCurrent	3531000
CY2022Q4	alxo	Accrued Clinical And Non Clinical Costs Current AccruedClinicalAndNonClinicalCostsCurrent	5485000
CY2023Q1	alxo	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	3197000
CY2022Q4	alxo	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	5249000
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2074000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3708000
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	797000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	835000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	777000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	755000
CY2023Q1	alxo	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	422000
CY2022Q4	alxo	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	2110000
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	179000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	286000
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	258000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	174000
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11235000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18602000
CY2023Q1	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company has non-cancelable operating leases for its offices located in the U.S. As of March 31, 2023, these leases expire on various dates between 2026 and 2030.
CY2023Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	Certain lease agreements include one or more options to renew, with renewal terms that can extend the lease up to two years after expiration.
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5400000
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	200000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1240000
CY2023Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	288000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	1267000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	1187000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	912000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	2069000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7980000
CY2023Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	288000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2143000
CY2023Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	109000
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5837000
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	179000
CY2023Q1	alxo	Operating Lease Liability Current Including Payable And Accrued Liabilities Due To Related Party OperatingLeaseLiabilityCurrentIncludingPayableAndAccruedLiabilitiesDueToRelatedParty	781000
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	179000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5056000
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5837000
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	179000
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y4M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.017
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	318000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	249000
CY2023Q1	alxo	Variable Lease Cost And Other Net VariableLeaseCostAndOtherNet	116000
CY2022Q1	alxo	Variable Lease Cost And Other Net VariableLeaseCostAndOtherNet	52000
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	44000
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	112000
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	112000
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000
CY2023Q1	us-gaap	Lease Cost LeaseCost	550000
CY2022Q1	us-gaap	Lease Cost LeaseCost	460000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	310000
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	169000
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1000
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	3000
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	107000
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	105000
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	435000
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	5217000
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4948000
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	10600000
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2023Q1	alxo	Term Loan Non Current TermLoanNonCurrent	10600000
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	941000
CY2023Q1	alxo	Term Loan Unamortized Final Payment TermLoanUnamortizedFinalPayment	209000
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9450000
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40863049
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40861386
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12730262
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6351000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5501000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30184000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24533000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40862513
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40862513
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40616302
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40616302
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7319186
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5456857
CY2023Q1	alxo	Number Of Pending Or Threatened Litigation NumberOfPendingOrThreatenedLitigation	0
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	14423000
CY2023Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	12303000
CY2023Q1	us-gaap	Purchase Obligation Due In Second And Third Year PurchaseObligationDueInSecondAndThirdYear	2090000
CY2023Q1	us-gaap	Purchase Obligation Due In Fourth And Fifth Year PurchaseObligationDueInFourthAndFifthYear	30000
CY2023Q1	us-gaap	Contractual Obligation ContractualObligation	14423000
CY2023Q1	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	12303000
CY2023Q1	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	2090000
CY2023Q1	us-gaap	Contractual Obligation Due In Fourth And Fifth Year ContractualObligationDueInFourthAndFifthYear	30000

Files In Submission

Name	View Source	Status
alxo-20230331_cal.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
0000950170-23-021247-index-headers.html	Edgar Link	pending
0000950170-23-021247-index.html	Edgar Link	pending
0000950170-23-021247.txt	Edgar Link	pending
0000950170-23-021247-xbrl.zip	Edgar Link	pending
alxo-20230331.htm	Edgar Link	pending
alxo-20230331.xsd	Edgar Link	pending
alxo-ex10_1.htm	Edgar Link	pending
alxo-ex31_1.htm	Edgar Link	pending
alxo-ex31_2.htm	Edgar Link	pending
alxo-ex32_1.htm	Edgar Link	pending
alxo-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
alxo-20230331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
alxo-20230331_pre.xml	Edgar Link	unprocessable
alxo-20230331_lab.xml	Edgar Link	unprocessable
alxo-20230331_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALXO
ALX ONCOLOGY HOLDINGS INC Stock $alxo

2023 Q2 Form 10-Q Financial Statement

#000095017023021247 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALXO ALX ONCOLOGY HOLDINGS INC Stock $alxo

2023 Q2 Form 10-Q Financial Statement

#000095017023021247 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALXO
ALX ONCOLOGY HOLDINGS INC Stock $alxo